"A remarkably young child’s diagnosis of a rare conjunctival stromal tumor underscores the importance of vigilance and comprehensive evaluation for even seemingly minor eyelid abnormalities, pushing the boundaries of known pediatric presentations for this enigmatic growth."
The case of an 18-month-old girl diagnosed with a conjunctival stromal tumor (COST) marks a significant point in the medical literature, not only for its rarity but also for the patient’s exceptionally young age. This finding, reported by ophthalmologists and pathologists at Vanderbilt University Medical Center, positions her as the youngest individual documented with this specific type of tumor and only the third child to be diagnosed with it. The growth’s unusual location on the punctum, the delicate opening responsible for tear drainage, further adds to the complexity and educational value of this case, prompting a deeper look into the nature of COST and the diagnostic considerations for ocular surface lesions in pediatric patients.
The initial observation occurred when the girl was approximately 14 months old. Her parents noticed a small, flesh-colored growth on the upper right eyelid. Over the subsequent months, this lesion gradually increased in size, conspicuously situated on the punctum, the tiny aperture that initiates the eye’s tear drainage pathway. When the child reached 18 months of age, she underwent surgical evaluation and complete removal of the growth. Subsequent laboratory analysis confirmed the presence of a conjunctival stromal tumor, a designation that signifies a rare type of ocular neoplasm first formally described in 2012.
The detailed case report, published online on June 11 and slated for inclusion in the September 2026 issue of the American Journal of Ophthalmology Case Reports, emphasizes the relative obscurity of COST. With fewer than 60 cases documented in the global medical literature since its initial description, it remains a condition with which many clinicians may not be intimately familiar. This underscores the critical role of specialized medical centers and thorough diagnostic workups when encountering unusual presentations, particularly in the pediatric population where the differential diagnosis for eyelid abnormalities can be broad.
According to the comprehensive report, the young patient presented with no significant pre-existing medical conditions, no history of ocular trauma, and no familial predisposition to syndromic disorders. An ophthalmological examination confirmed that the growth was not directly attached to the eyeball itself. The tumor’s specific location was noted as particularly unusual. While conjunctival stromal tumors are most commonly identified on the bulbar conjunctiva—the transparent membrane that covers the white part of the eye—this particular lesion appeared to originate from or involve the punctum.
The punctum serves as the crucial entry point into the eye’s intricate tear drainage system. As explained by health authorities like the Cleveland Clinic, each eye possesses two puncta, one on the upper eyelid and one on the lower. These function akin to miniature drains, collecting tears that then flow through a series of small channels, ultimately emptying into the nasal passages. The obstruction or abnormal growth in this area can lead to symptoms such as excessive tearing (epiphora) or, conversely, dryness if the drainage pathway is significantly compromised.
During the surgical intervention, the mass was observed to emanate from the punctal region. Surgeons meticulously removed the affected portion of the punctum along with the tumor, while taking care to preserve the integrity of the remaining tear drainage system. The excised lesion measured approximately 0.7 by 0.6 by 0.4 centimeters, a size less than a third of an inch across. Macroscopically, it was described as having an ivory hue and a gelatinous consistency, providing initial clues to its pathological nature.
Microscopic examination by pathologists revealed a well-demarcated, polyp-like nodule. Histologically, it was characterized by bland spindle-shaped cells, some exhibiting pseudonuclear inclusions—an artifactual appearance within the cell nucleus. Interspersed among these were multinucleated giant cells, a feature that, when their multiple nuclei formed characteristic flower-like patterns, were described as "florets." The surface of the tumor was predominantly covered by stratified squamous tissue, with only a limited area lined by conjunctival epithelium. Immunohistochemical staining, employing special markers, demonstrated that the spindle cells were positive for BCL-2 and CD34. This specific immunophenotype is considered a hallmark consistent with the diagnosis of conjunctival stromal tumor.
COST was initially identified and characterized in a 2012 case series as a benign mesenchymal proliferation, meaning it was recognized as a non-cancerous growth originating from connective tissue cells. The World Health Organization (WHO) currently categorizes COST as a type of fibrous or fibroblastic tumor, placing it on a spectrum with other benign growths such as ocular surface fibromas, as noted by the authors of the current report.
The incidence of COST is remarkably low, estimated to account for less than 0.001% to a maximum of 0.2% of all conjunctival lesions. The precise etiology of these tumors remains largely unknown. However, researchers hypothesize that they may arise secondary to reactive or inflammatory processes within the conjunctiva. Historically, COST has been observed most frequently in middle-aged adults, making its occurrence in an infant particularly noteworthy and prompting re-evaluation of its typical demographic profile.
Prior to this recent report, COST had been documented in pediatric patients on only two prior occasions. The authors of the Vanderbilt study advocate for the inclusion of COST in the differential diagnosis when evaluating any conjunctival lesion, irrespective of the patient’s age. This broadens the diagnostic net and ensures that rare possibilities are not overlooked in the face of more common presentations.
Furthermore, the report emphasizes the critical importance of differentiating COST from conjunctival myxoma, another type of conjunctival growth. Conjunctival myxomas have known associations with certain systemic syndromes, and their presence can sometimes indicate underlying, potentially undiagnosed, systemic conditions. For instance, a previously published case report on a conjunctival myxoid stromal tumor highlighted that such growths could serve as markers for conditions like Carney complex and Zollinger-Ellison syndrome. The distinction is vital for appropriate patient management and the identification of potential co-existing health issues.
While COST is classified as benign, this designation does not always equate to a straightforward clinical course. A separate case report, published in the same journal in April by researchers from Montreal, described a 43-year-old man whose COST exhibited aggressive behavior. The tumor recurred multiple times following three surgical excisions and showed minimal response to radiation therapy. Ultimately, the patient required the removal of the contents of his eye socket to prevent the tumor’s extension into the cranial cavity. Despite this extensive intervention, he has remained recurrence-free for 32 months post-surgery. This case serves as a potent reminder that the behavior of COST can be variable and its long-term trajectory is still being actively studied and defined.
In the case of the 18-month-old girl, she is currently under regular follow-up, and thus far, there is no evidence to suggest a recurrence of the tumor. Definitive confirmation of the diagnosis was achieved through complete surgical excision and thorough histopathological examination, a more robust approach than relying solely on clinical appearance. Longer-term monitoring will be essential to ascertain her prognosis and ensure no late complications arise.
As a single case report, this study cannot definitively establish the prevalence of COST in very young children or elucidate whether its behavior differs significantly from that observed in adults. However, it undeniably pushes the known age of onset for this tumor to a younger demographic than previously recorded.
Many common eye complaints in infants and toddlers have straightforward explanations. For example, blocked tear ducts are a frequent occurrence, affecting an estimated 6% to 20% of infants, according to the Cleveland Clinic. This institution also lists growths, both benign and, less commonly, malignant, as potential causes of tear duct obstruction. Therefore, parents who observe any new or growing lump on or in the vicinity of their child’s eyelid are strongly advised to seek prompt evaluation from a pediatrician or a specialized eye care professional to ensure accurate diagnosis and timely management. The unfolding understanding of rare conditions like COST highlights the continuous evolution of medical knowledge and the importance of documenting and sharing unusual clinical presentations.
